This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Virtanen, S. S. Articles by Lakkakorpi, P. T. Search for Related Content PubMed PubMed Citation Articles by Virtanen, S. S. Articles by Lakkakorpi, P. T.

Alendronate Inhibits Invasion of PC-3 Prostate Cancer Cells by Affecting the Mevalonate Pathway¹

Institute of Biomedicine, Department of Anatomy and Medicity Research Laboratory, University of Turku, FIN-20520 Turku, Finland

Breast and prostate cancer preferentially metastasize in the skeleton, inducinglocally increased bone resorption by osteoclasts. Bisphosphonates (BPs), potent inhibitors of osteoclasts and bone resorption, are able to reduce metastatic bone lesions, but the metastasis-related cellular target molecules for BPs have not yet been identified. In osteoclasts, nitrogen-containing BPs inhibit the function of the mevalonate pathway, impairing the prenylation and activation of small GTPases. In addition, direct effects of BPs on cancer cells have been suggested. In the present study, the effects of two clinically used BPs, the amino-BP alendronate and clodronate, on adhesion, invasion, and migration of human PC-3 prostate cancer cells were examined in vitro. We also studied the possible role of the mevalonate pathway in invasion and migration of PC-3 cells using the ß-hydroxy-ß-methylglutaryl-CoA reductase inhibitor mevastatin and the mevalonate pathway intermediates mevalonate (mevalonic acid lactone), geranylgeraniol, and trans-trans-farnesol. The results demonstrate that alendronate pretreatment very effectively inhibited in vitro invasion of prostate cancer cells in a dose-dependent manner, with an IC₅₀ as low as 1 pM. The inhibition was similar to that of mevastatin. Clodronate also inhibited invasion, but the IC₅₀ was 0.1 µM. Importantly, geranylgeraniol and trans-trans-farnesol reversed the inhibitory effect of alendronate and mevastatin but not the clodronate-induced inhibition of invasion. Alendronate pretreatment also inhibited migration, which was partially reversed by geranylgeraniol and trans-trans-farnesol. Adhesion of PC-3 cells to various matrices was reduced, and their F-actin organization was changed. Alendronate pretreatment also inhibited invasion of human Du-145 prostate and MDA-MB-231 breast cancer cells. As a conclusion, the results demonstrate that the mevalonate pathway leading to protein prenylation is important for cancer cell invasion and migration in vitro. They further suggest that interference with this pathway is involved in inhibition of invasion and migration of prostate cancer cells by the amino-BP alendronate but that the mechanism of clodronate inhibition is different. It is possible that BPs have therapeutic potential in preventing the spread of prostate cancer.

This article has been cited by other articles:

				C. L. Bailey, P. Kelly, and P. J. Casey Activation of Rap1 Promotes Prostate Cancer Metastasis Cancer Res., June 15, 2009; 69(12): 4962 - 4968. [Abstract] [Full Text] [PDF]

				N. Lu, Y. Ling, Y. Gao, Y. Chen, R. Mu, Q. Qi, W. Liu, H. Zhang, H. Gu, S. Wang, et al. Endostar Suppresses Invasion Through Downregulating the Expression of Matrix Metalloproteinase-2/9 in MDA-MB-435 Human Breast Cancer Cells Experimental Biology and Medicine, August 1, 2008; 233(8): 1013 - 1020. [Abstract] [Full Text] [PDF]

				C. R. Evelyn, S. M. Wade, Q. Wang, M. Wu, J. A. Iniguez-Lluhi, S. D. Merajver, and R. R. Neubig CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling Mol. Cancer Ther., August 1, 2007; 6(8): 2249 - 2260. [Abstract] [Full Text] [PDF]

				A. J. Roelofs, K. Thompson, S. Gordon, and M. J. Rogers Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res., October 15, 2006; 12(20): 6222s - 6230s. [Abstract] [Full Text] [PDF]

				M. A. Merrell, J. M. Ilvesaro, N. Lehtonen, T. Sorsa, B. Gehrs, E. Rosenthal, D. Chen, B. Shackley, K. W. Harris, and K. S. Selander Toll-Like Receptor 9 Agonists Promote Cellular Invasion by Increasing Matrix Metalloproteinase Activity Mol. Cancer Res., July 1, 2006; 4(7): 437 - 447. [Abstract] [Full Text] [PDF]

				M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer, March 1, 2006; 13(1): 7 - 26. [Abstract] [Full Text] [PDF]

				G A Clines and T A Guise Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone Endocr. Relat. Cancer, September 1, 2005; 12(3): 549 - 583. [Abstract] [Full Text] [PDF]

				G. van der Pluijm, I. Que, B. Sijmons, J. T. Buijs, C. W.G.M. Lowik, A. Wetterwald, G. N. Thalmann, S. E. Papapoulos, and M. G. Cecchini Interference with the Microenvironmental Support Impairs the De novo Formation of Bone Metastases In vivo Cancer Res., September 1, 2005; 65(17): 7682 - 7690. [Abstract] [Full Text] [PDF]

				K. Hashimoto, K.-i. Morishige, K. Sawada, M. Tahara, R. Kawagishi, Y. Ikebuchi, M. Sakata, K. Tasaka, and Y. Murata Alendronate Inhibits Intraperitoneal Dissemination in In vivo Ovarian Cancer Model Cancer Res., January 15, 2005; 65(2): 540 - 545. [Abstract] [Full Text] [PDF]

				J. R. Green Bisphosphonates: Preclinical Review Oncologist, September 1, 2004; 9(suppl_4): 3 - 13. [Abstract] [Full Text] [PDF]

				T. Hiraga, P. J. Williams, A. Ueda, D. Tamura, and T. Yoneda Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model Clin. Cancer Res., July 1, 2004; 10(13): 4559 - 4567. [Abstract] [Full Text] [PDF]

				V. B. Andela, P. T. Lakkakorpi, H. K. Vaananen, P. L. Harkonen, K. Sawada, K.-i. Morishige, M. Tahara, R. Kawagishi, Y. Ikebuchi, K. Tasaka, et al. Correspondence Re S. S. Virtanen et al., Alendronate Inhibits Invasion of PC-3 Prostate Cancer Cells by Affecting the Mevalonate Pathway. Cancer Res 2002;62:2708-14. Re K. Sawada et al., Alendronate Inhibits Lysophosphatidic Acid-Induced Migration of Human Ovarian Cancer Cells by Attenuating the Activation of Rho. Cancer Res 2002;62:6015-20. Cancer Res., April 15, 2004; 64(8): 2934 - 2936. [Full Text] [PDF]

				J. Kuroda, S. Kimura, H. Segawa, Y. Kobayashi, T. Yoshikawa, Y. Urasaki, T. Ueda, F. Enjo, H. Tokuda, O. G. Ottmann, et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate Blood, September 15, 2003; 102(6): 2229 - 2235. [Abstract] [Full Text] [PDF]

				M. J. Morris and H. I. Scher Clinical Approaches to Osseous Metastases in Prostate Cancer Oncologist, April 1, 2003; 8(2): 161 - 173. [Abstract] [Full Text] [PDF]

				P. Fournier, S. Boissier, S. Filleur, J. Guglielmi, F. Cabon, M. Colombel, and P. Clezardin Bisphosphonates Inhibit Angiogenesis in Vitro and Testosterone-stimulated Vascular Regrowth in the Ventral Prostate in Castrated Rats Cancer Res., November 15, 2002; 62(22): 6538 - 6544. [Abstract] [Full Text] [PDF]

				K. Sawada, K.-i. Morishige, M. Tahara, R. Kawagishi, Y. Ikebuchi, K. Tasaka, and Y. Murata Alendronate Inhibits Lysophosphatidic Acid-induced Migration of Human Ovarian Cancer Cells by Attenuating the Activation of Rho Cancer Res., November 1, 2002; 62(21): 6015 - 6020. [Abstract] [Full Text] [PDF]